ERBB2 and neoplasm: By combining the CD47 blockade with a tumor-specific antigen (e.g., CD47 × DLL3, CD47 × HER2, or CD47 × CLDN 18.2), it may be possible to selectively restore macrophage-driven tumor clearance while minimizing systemic toxicity associated with global CD47 inhibition.